Cumulative Benefit over 52 Weeks with Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis
Dermatology and Therapy（2024）
关键词
Apremilast,cumulative clinical benefit,Deucravacitinib,Oral treatments,Psoriasis,Small molecules
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要